• 1
    Gurney JG, Swensen AR, Bulterys M. Malignant bone tumors. In: RiesLAG, SmithMA, GumeyJG, et al., editors. Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975–1995. NIH Pub. No. 99–4649. Bethesda, MD: National Cancer Institute, SEER Program; 1999.
  • 2
    Rodriguez-Galindo C, Spunt SL, Pappo AS. Treatment of Ewing sarcoma family of tumors: current status and outlook for the future. Med Pediatr Oncol. 2003; 40: 276287.
  • 3
    Marina NM, Pappo AS, Parham DM, et al. Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round cell tumor: a feasibility study at St. Jude Children's Research Hospital. J Clin Oncol. 1999; 17: 180190.
  • 4
    Craft AW, Paulussen M, Douglas C, Mapp T, Lewis IB, Jurgens H. EICESS 92-Early results of an international Ewings tumour study. Med Pediatr Oncol. 2000; 35: 191. Abstract.
  • 5
    Granowetter L, Womer R, Devidas M, et al. Comparison of dose intensified and standard dose chemotherapy for the treatment of non-metastatic Ewing's sarcoma (ES) and primitive neuroectodermal tumor (PNET) of bone and soft tissue: a Pediatric Oncology Group-Children's Cancer Group phase III trial. Med Pediatr Oncol. 2001; 37: 172. Abstract.
  • 6
    Hayes FA, Thompson EI, Meyer WH, et al. Therapy for localized Ewing's sarcoma of bone. J Clin Oncol. 1989; 7: 208213.
  • 7
    Meyer WH, Kun L, Marina N, et al. Ifosfamide plus etoposide in newly diagnosed Ewing's sarcoma of the bone. J Clin Oncol. 1992; 10: 17371742.
  • 8
    Navid F, Santana VM, Billups CA, et al. Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas. Cancer. 2006; 106: 18461856.
  • 9
    Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: John Wiley & Sons; 1980.
  • 10
    Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988; 16: 11411154.
  • 11
    Burgert EO, Nesbit ME, Garnsey LA, et al. Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: Intergroup Study IESS-II. J Clin Oncol. 1990; 8: 15141524.
  • 12
    Craft AW, Cotterill SJ, Bullimore JA, Pearson D. Long-term results from the first UKCCSG Ewing's tumour study (ET-1). Eur J Cancer. 1997; 33: 10611069.
  • 13
    Jurgens H, Exner U, Gadner H, et al. Multidisciplinary treatment of primary Ewing's sarcoma of bone. Cancer. 1988; 61: 2332.
  • 14
    Bacci G, Toni A, Avella M, et al. Long-term results in 144 localized Ewing's sarcoma patients treated with combined therapy. Cancer. 1989; 63: 14771486.
  • 15
    Donaldson SS, Torrey M, Link MP, et al. A multidisciplinary study investigating radiotherapy in Ewing's sarcoma: end results of POG #8346. Int J Radiat Oncol Biol Phys. 1998; 42: 125135.
  • 16
    Oberlin O, Le Deley MC, N'Guyen Bui B, et al. Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study). Br J Cancer. 2001; 85: 646654.
  • 17
    Nesbit ME, Gehan EA, Burgert EO, et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the first intergroup study. J Clin Oncol. 1990; 8: 16641674.
  • 18
    Razek A, Perez CA, Tefft M, et al. Intergroup Ewing's Sarcoma Study: local control related to radiation dose, volume, and site of primary lesion in Ewing's sarcoma. Cancer. 1980; 46: 516521.
  • 19
    Evans RG, Nesbit ME, Gehan EA, et al. Multimodal therapy for the management of localized Ewing's sarcoma of pelvic and sacral bones: a report from the Second Intergroup Study. J Clin Oncol. 1991; 9: 11731180.
  • 20
    Miser JS, Kinsella TJ, Triche TJ, et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol. 1987; 5: 11911198.
  • 21
    Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003; 348: 694701.
  • 22
    Schuler U, Ehninger G, Wagner T. Repeated high-dose cyclophosphamide administration in bone marrow transplantation: exposure to activated metabolites. Cancer Chemother Pharmacol. 1987; 20: 248252.
  • 23
    Sladek NE, Doeden D, Powers JF, Krivit W. Plasma concentration of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation. Cancer Treat Rep. 1984; 68: 12471254.
  • 24
    Kurowski V, Wagner T. Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetylaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy. Cancer Chemother Pharmacol. 1993; 33: 3642.
  • 25
    Boddy AV, Yule SM, Wyllie R, Price L, Pearson AD, Idle JR. Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children. Cancer Res. 1993; 53: 37583764.
  • 26
    Comandone A, Leone L, Oliva C, et al. Pharmacokinetics of ifosfamide administered according to three different schedules in metastatic soft tissue and bone sarcomas. J Chemother. 1998; 10: 385393.
  • 27
    Busse D, Busch FW, Bohnenstengel F, et al. Dose escalation of cyclophosphamide in patients with breast cancer: consequences for pharmacokinetics and metabolism. J Clin Oncol. 1997; 15: 18851896.
  • 28
    Ren S, Yang JS, Kalhorn TF, Slattery JT. Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and dechloroethylcyclophosphamide in human liver microsomes. Cancer Res. 1997; 57: 42294235.
  • 29
    Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol. 2000; 18: 31083114.
  • 30
    Bacci G, Ferrari S, Bertoni F, et al. Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol. 2000; 18: 411.
  • 31
    Miser JS, Krailo MD, Tarbell NJ, et al. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide: a children's Cancer Group and Pediatric Oncology Group study. J Clin Oncol. 2004; 22: 28732876.
  • 32
    Paulussen M, Ahrens S, Burdach S, et al. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. Ann Oncol. 1998; 9: 275281.
  • 33
    Kolb EA, Kushner BH, Gorlick R, et al. Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. J Clin Oncol. 2003; 21: 34233430.
  • 34
    Paulussen M, Ahrens S, Lehnert M, et al. Second malignancies after Ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study. Ann Oncol. 2001; 12: 16191630.
  • 35
    Kuttesch JF, Wexler LH, Marcus RB, et al. Second malignancies after Ewing's sarcoma: radiation dose-dependency of secondary sarcomas. J Clin Oncol. 1996; 14: 28182825.
  • 36
    Bacci G, Forni C, Longhi A, et al. Long-term outcome for patients with non-metastatic Ewing's sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and 1992. Eur J Cancer. 2004; 40: 7383.
  • 37
    Rodriguez-Galindo C, Poquette CA, Marina NM, et al. Hematologic abnormalities and acute myeloid leukemia in children and adolescents administered intensified chemotherapy for the Ewing sarcoma family of tumors. J Pediatr Hematol Oncol. 2000; 22: 321329.
  • 38
    Miser JS, Krailo M, Meyers P, et al. Metastatic Ewing's sarcoma (ES) and primitive neuroectodermal tumor (PNET) of bone: failure of new regimens to improve outcome. Proc Annu Meet Am Soc Clin Oncol. 1996; 15: 467. Abstract.
  • 39
    Kushner BH, Heller G, Cheung NK, et al. High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors. J Clin Oncol. 1998; 16: 30163020.
  • 40
    Paulussen M, Ahrens S, Dunst J, et al. Localized Ewing tumor of bone: final results of the Cooperative Ewing's Sarcoma Study CESS-86. J Clin Oncol. 2001; 19: 18181829.
  • 41
    Schleiermacher G, Peter M, Oberlin O, et al. Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized Ewing tumor. J Clin Oncol. 2003; 21: 8591.